Drugs / MMA-101
MMA-101
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05778877 | Dec 2022 → Aug 2025 | methylmalonic acidemia | Selecta Biosciences, Inc. | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MMA-101 | “a gene transfer therapy that is using an inactive virus, called adeno-associated-virus 8 (AAV8), to deliver the MMUT gene to the liver, by itself called MMA-101” NCT05778877 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “a gene transfer therapy that is using an inactive virus, called adeno-associated-virus 8 (AAV8)” NCT05778877 ↗ |
| Route | Intravenous | “IV infusion of MMA-101 in the first patient on Day 1” NCT05778877 ↗ |
| Target | MMUT | “deliver the MMUT gene to the liver” NCT05778877 ↗ |